Valuation: PREDILIFE

Market Cap 1.14Cr 1.3Cr 1.05Cr 98.14L 1.84Cr 122.36Cr 1.88Cr 13Cr 4.88Cr 60Cr 4.87Cr 4.76Cr 209.69Cr P/E 2023
-5x
P/E 2024 -3.18x
Enterprise Value 1.49Cr 1.7Cr 1.37Cr 1.29Cr 2.41Cr 160.43Cr 2.46Cr 17Cr 6.39Cr 79Cr 6.39Cr 6.25Cr 274.93Cr EV / Sales 2023
77.9x
EV / Sales 2024 34.5x
Free-Float
26.25%
Yield 2023 *
-
Yield 2024 -
1 week-1.63%
Current month-16.61%
1 month-16.90%
3 months-22.01%
6 months-26.97%
Current year-19.93%
1 week 2.28
Extreme 2.28
2.41
1 month 2.28
Extreme 2.28
2.89
Current year 2.28
Extreme 2.28
4
1 year 2.28
Extreme 2.28
4
3 years 2.28
Extreme 2.28
24
5 years 2.28
Extreme 2.28
24
10 years 2.28
Extreme 2.28
24
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2004
Chief Tech/Sci/R&D Officer - 01/01/2007
General Counsel - 01/01/2016
Director TitleAgeSince
Director/Board Member 46 01/01/2018
Chairman 56 01/01/2004
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
27/23/27Buy

Chief Executive Officer

1,200 0.0328%
23/22/23Sell

Chief Executive Officer

3,000 0.0820%
09/22/09Buy

Chief Executive Officer

2,000 0.0546%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.63%-34.69%-59.15% 1.04Cr
+3.31%+12.79%+120.93%+138.62% 482.67Cr
+3.51%+19.57%+77.78%+208.24% 335.45Cr
-4.54%-2.42%-29.51%-42.19% 195.58Cr
+0.95%+8.70%+151.48%-43.71% 189.76Cr
+3.48%+10.08%+49.87%+232.41% 148.88Cr
+1.63%+19.62%+151.82%-50.40% 92Cr
-3.95%+0.72%-15.15%+32.70% 84Cr
-1.09%-7.70%-38.35%-21.85% 47Cr
-8.07%-26.89%-0.51% - 43Cr
Average -0.48%+3.96%+43.37%+43.85% 161.94Cr
Weighted average by Cap. +1.24%+9.71%+77.60%+96.36%

Financials

2023 2024
Net sales 3L 4L 3L 3L 5L 3.42Cr 5L 35.21L 13.62L 1.69Cr 13.61L 13.31L 5.86Cr 5L 6L 5L 4L 8L 5.31Cr 8L 54.64L 21.14L 2.62Cr 21.12L 20.66L 9.09Cr
Net income -42.24L -48.18L -38.94L -36.45L -68.35L -45Cr -69.77L -4.68Cr -1.81Cr -22Cr -1.81Cr -1.77Cr -78Cr -42.65L -48.64L -39.31L -36.8L -69.01L -46Cr -70.45L -4.72Cr -1.83Cr -23Cr -1.83Cr -1.79Cr -79Cr
Net Debt 40L 45.62L 36.87L 34.52L 64.73L 43Cr 66.07L 4.43Cr 1.71Cr 21Cr 1.71Cr 1.68Cr 74Cr 35.38L 40.36L 32.62L 30.54L 57.26L 38Cr 58.45L 3.92Cr 1.52Cr 19Cr 1.52Cr 1.48Cr 65Cr
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women,over 300,000 French women and 500,000 English. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
27
Date Price Change Volume
26/26/26 €2.410 0.00% 360
25/26/25 €2.410 +0.42% 53
24/26/24 €2.400 0.00% 465
23/26/23 €2.400 0.00% 220
22/26/22 €2.400 -2.04% 227

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALPRE Stock